NCT04395586

Brief Summary

The characteristics of patients as well as microbiologic profile of culture-proven infection will be studies in conjunction with clinical outcome within 28-days

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2020

Shorter than P25 for all trials

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 15, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 20, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

July 1, 2020

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2021

Completed
Last Updated

January 3, 2022

Status Verified

December 1, 2021

Enrollment Period

12 months

First QC Date

May 15, 2020

Last Update Submit

December 11, 2021

Conditions

Culture-proven Infection

Outcome Measures

Primary Outcomes (1)

  • Mortality

    All-cause and disease specific mortality

    28 days

Study Arms (1)

Culture-proven infected patients

Other: Culture

Interventions

CultureOTHER

Culture

Culture-proven infected patients

Eligibility Criteria

Age13 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Any individual aged ≥13 year old requested for him/her bacterial/fungal culture.

You may qualify if:

  • Any individual aged ≥13 year old requested for him/her bacterial/fungal culture.
  • Able to provide a written informed consent.

You may not qualify if:

  • Age \<13 years old.
  • Unable/unwilling to provide a written informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

Study will include a sample from blood, cerebrospinal fluid, intra-articular fluid, peritoneal fluid, pleural fluid, sputum, tissue (e.g., skin, bone, and cartilages), and urine.

MeSH Terms

Interventions

Culture Techniques

Intervention Hierarchy (Ancestors)

In Vitro TechniquesInvestigative Techniques

Study Officials

  • Abdullah M Algarni, MBBS

    Aseer Central Hospital

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Family medicine senior registrar

Study Record Dates

First Submitted

May 15, 2020

First Posted

May 20, 2020

Study Start

July 1, 2020

Primary Completion

June 30, 2021

Study Completion

June 30, 2021

Last Updated

January 3, 2022

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will not share